Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADIMAC phase II PAD induction with MRD-guided deferred ASCT in untreated multiple myeloma
2010-021598-35Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by University College London. Primary endpoints: Progression-free survival in deferred-treatment patients by MRD status and 2-year progression-free survival in CR/VGPR patients without further treatment. Started Jul 2010; status: completed.
02
Drugs
bortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-021598-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021598-35.